Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results

Author:

Shapiro Amy D.1,Angchaisuksiri Pantep2,Astermark Jan3ORCID,Benson Gary4,Castaman Giancarlo5,Chowdary Pratima6,Eichler Hermann7,Jiménez-Yuste Victor8ORCID,Kavakli Kaan9,Matsushita Tadashi10,Poulsen Lone Hvitfeldt11,Wheeler Allison P.12,Young Guy13,Zupancic-Salek Silva141516,Oldenburg Johannes1718

Affiliation:

1. Indiana Hemophilia and Thrombosis Center, Indianapolis, IN;

2. Division of Hematology, Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand;

3. Center for Thrombosis and Haemostasis, Lund University, Skåne University Hospital, Malmö, Sweden;

4. Department of Hematology, Belfast Health and Social Care Trust, Belfast, United Kingdom;

5. Center for Bleeding Disorders and Coagulation, Department of Oncology, Careggi University Hospital, Florence, Italy;

6. Katharine Dormandy Hemophilia Centre and Thrombosis Unit, Royal Free London NHS Foundation Trust, London, United Kingdom;

7. Institute of Clinical Hemostaseology and Transfusion Medicine, Saarland University and University Hospital, Homburg, Saar, Germany;

8. Haematology Department, La Paz University Hospital, Universidad Autónoma Madrid, Madrid, Spain;

9. Department of Hematology, Ege University Children’s Hospital, Izmir, Turkey;

10. Department of Transfusion Medicine, Nagoya University Hospital, Nagoya, Japan;

11. The Hemophilia Centre, Department of Haematology, Aarhus University, Aarhus, Denmark;

12. Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN;

13. Hemostasis and Thrombosis Center, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, CA;

14. Department of Haematology, and Haemophilia and Thrombosis Unit, University Hospital Centre Zagreb, Zagreb, Croatia;

15. School of Medicine, University of Osijek, Osijek, Croatia;

16. School of Medicine, University of Zagreb, Zagreb, Croatia; and

17. Department of Immunohematology and

18. Department of Molecular Hemostasis, Institute of Experimental Hematology and Transfusion Medicine, University Clinic, Bonn, Germany

Abstract

Tissue factor pathway inhibitor (TFPI) inhibits coagulation initiation, and TFPI inhibition enhances the activation of factor X by tissue factor. Shapiro et al report the results of a phase 2 study of prophylactic administration of the TFPI inhibitor concizumab for bleeding prevention in hemophilia, reporting efficacy in Factor VIII and IX deficiency even in patients with inhibitors to Factor VIII or IX.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3